Zobrazeno 1 - 10
of 58
pro vyhledávání: '"K. R. Hande"'
Publikováno v:
Renal Failure. 17:117-123
The ability of a 13 amino-acid analog of atrial natriuretic peptide (ANP), A68828, to prevent development of cisplatin toxicity was evaluated in a rat model. ANP (1 microgram/kg/min), A68828 (10 micrograms/kg/min), A68828 (50 micrograms/kg/min), or p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::308bdd43449ae0f02589c127046ae0d5
https://doi.org/10.3109/08860229509026248
https://doi.org/10.3109/08860229509026248
Publikováno v:
Journal of Clinical Oncology. 8:1613-1617
Twenty-two patients with recurrent small-cell lung cancer (SCLC) were treated with single-agent etoposide 50 mg/m2/d by mouth for 21 consecutive days. Eleven patients had received previous chemotherapy with cyclophosphamide, doxorubicin, and vincrist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f6bcf9218511a8d3197aee026d5b735
https://doi.org/10.1200/jco.1990.8.10.1613
https://doi.org/10.1200/jco.1990.8.10.1613
Autor:
R Brown, E. A. Harden, Roger H. Herzig, L. Pineiro, Brian James Bolwell, Steven N. Wolff, D. Frei-Lahr, Geoffrey P. Herzig, J. N. Lowder, K. R. Hande
Publikováno v:
Blood. 76:473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d350de1dde93e7728257dcda1d2874df
https://doi.org/10.1182/blood.v76.3.473.473
https://doi.org/10.1182/blood.v76.3.473.473
Autor:
T R, Toonen, K R, Hande
Publikováno v:
Cancer chemotherapy and biological response modifiers. 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::58bf70557c386ae8ba5ad207309f6429
https://pubmed.ncbi.nlm.nih.gov/11686011
https://pubmed.ncbi.nlm.nih.gov/11686011
Publikováno v:
Cancer. 91(3)
Current therapy for patients with carcinoma of an unknown primary site (CUP) is inadequate. To develop less toxic and more effective therapies for patients with CUP, a multicenter, randomized, Phase II study was conducted. Patients with CUP received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eb276964f8a392c2ec7f791202b4373c
https://pubmed.ncbi.nlm.nih.gov/11169943
https://pubmed.ncbi.nlm.nih.gov/11169943
Autor:
H, Choy, A, Chakravarthy, R F, Devore, M, Jagasia, K R, Hande, J R, Roberts, D H, Johnson, F, Yunus
Publikováno v:
Oncology (Williston Park, N.Y.). 14(7 Suppl 5)
In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a phase I trial to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab0e51d9151b5ffe87b58127f7033251
https://pubmed.ncbi.nlm.nih.gov/10981290
https://pubmed.ncbi.nlm.nih.gov/10981290
Autor:
H, Choy, R F, DeVore, K R, Hande, L L, Porter, P, Rosenblatt, F, Yunus, L, Schlabach, C, Smith, Y, Shyr, K, LaPorte, D H, Johnson
Publikováno v:
Seminars in oncology. 24(4 Suppl 12)
We conducted a prospective phase II study to determine the response rate, toxicity profile, and survival rate among patients with locally advanced unresectable non-small cell lung cancer receiving concurrent weekly paclitaxel (Taxol; Bristol-Myers Sq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44adb042787d5ab43867e252870229df
https://pubmed.ncbi.nlm.nih.gov/9331115
https://pubmed.ncbi.nlm.nih.gov/9331115
Publikováno v:
Seminars in oncology. 24(4 Suppl 11)
Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b84fc4ef813407c81939f4f31b284283
https://pubmed.ncbi.nlm.nih.gov/9314294
https://pubmed.ncbi.nlm.nih.gov/9314294
Publikováno v:
Seminars in oncology. 24(1 Suppl 3)
5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients. Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c54471baa64dff1bc433aea536bfd45b
https://pubmed.ncbi.nlm.nih.gov/9071336
https://pubmed.ncbi.nlm.nih.gov/9071336
Publikováno v:
Seminars in oncology. 23(6 Suppl 16)
In studies conducted by the Eastern Cooperative Oncology Group, treatment with either paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) or carboplatin was associated with an improvement in 1-year survival in patients with stage IV non-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::265c71faf21e9e2b884ce664d88a4532
https://pubmed.ncbi.nlm.nih.gov/9007120
https://pubmed.ncbi.nlm.nih.gov/9007120